LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Jul 21, 2023
Product Development
Vir’s first shot at ‘day one solution’ for influenza A misses Phase II endpoints
Prophylactic mAb was positioned as a bulwark against a potential flu pandemic
Read More
BioCentury
|
Jan 31, 2023
Distillery Therapeutics
A broadly acting neuraminidase-targeted mAb for influenza
Read More
BioCentury
|
Sep 6, 2022
Distillery Therapeutics
A single-dose inactivated whole-virus vaccine for influenza A
Read More
BioCentury
|
Dec 11, 2021
Product Development
Without clear differentiation, Moderna flu readout dents shares
First Phase I data for seasonal flu vaccine draw comparison to existing product, raise concerns about adverse events
Read More
BioCentury
|
Nov 7, 2020
Translation in Brief
Neoleukin’s ACE2 decoy protects hamsters from SARS-CoV-2; plus a circular RNA linked to diabetes and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Oct 3, 2020
Translation in Brief
A SARS-CoV-2 genome degrader; neutralizing influenza B mAbs; Fulcrum’s sickle cell therapy increases fetal hemoglobin and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Feb 13, 2020
Emerging Company Profile
Pneumagen: out-competing viral sugar binding to prevent infection
Pneumagen targeting infections, cancer by co-opting and enhancing microbial carbohydrate binders
Read More
BioCentury
|
Dec 5, 2019
Company News
Deerfield propels Civetta with $53M series A
How Civetta is using its series A from Deerfield to take on β-propeller proteins as a target class
Read More
BioCentury
|
Oct 24, 2019
Preclinical News
Oct. 24 Preclinical Quick Takes: anti-neuraminidase human antibodies for broad flu protection; plus Ionis-Baylor, Merck and more
Read More
BioCentury
|
Jul 25, 2019
Product Development
The universe of universal flu vaccines
How companies are broadening the reach of flu vaccines beyond seasonal strains
Read More
Items per page:
10
1 - 10 of 519